According to the US Food and Drug Administration (FDA), the increase in the shortage of critical drugs could potentially become a major public health emergency.
According to the US Food and Drug Administration (FDA), the increase in the shortage of critical drugs could potentially become a major “public health emergency.” The number tripled from 2005 to 2010 and this disruption in drug treatment supplies caused an increase in healthcare costs, delays in medical procedures, and cancelled drug studies. At the Academy of Managed Care Pharmacy (AMCP) 24th Annual Meeting, Senior Drug Information Specialist, Sherry Andes, PharmD, BCPS, BCPP, PAHM, from informedRX Inc (a subsidiary of SXC Health Solutions Inc), and Joseph Hill, MA, Director, Federal Legislative Affairs, American Society of Health-System Pharmacists, led the session, “Drug Shortages and the Impact on Managed Care Pharmacy” discussing the cause, effects, and potential solutions for addressing this concern.
The following 4 drug classes have been affected the most by the shortages: the central nervous system, antibiotics, chemotherapy, and cardiovascular. According to the University of Utah Drug Information Service 60% to 70% of the reported shortages were injectable therapies. As reported by the FDA Drug Shortage Program, the largest reason for the shortages was the quality of product (42%). Other reasons were production/capacity and product discontinuation issues, as well as unavailability of raw materials and other components. Time is also spent managing the drug shortage issue, with pharmacists losing up to 9 hours per week and pharmacy technicians 8 hours per week.
Potential solutions for these drug shortages involve legislation with bipartisan bills introduced to Congress in 2011. New legislation to establish early warning systems would force manufacturers to notify the FDA of an interruption in production and require them to establish a contingency plan. According to the FDA, in 2011, 195 additional shortages were prevented when manufacturers provided confidential and advance notice of pending shortages. There is significant interest in addressing this issue by Congress.
For more information on this and other sessions, please visit www.amcp.org.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More